Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer

Summary

The purpose of this study is to see if women with bone metastases from breast cancer will benefit from the addition of doxycycline to their standard bone-targeted therapy. Participants will be asked to take 100 mg of Doxycycline orally twice a day for 12 weeks. Blood and tissue collection will further define the mechanism of the benefits if there are any.

Timeline

Start

2013-08

Primary completion

2017-11

Completion

2017-11

Drugs

Indications

No indication recorded.